Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Inhibikase Therapeutics Inc IKT

Healthcare Biotechnology
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease... see more

Recent & Breaking News (NDAQ:IKT)

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

GlobeNewswire November 14, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 21, 2024

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

GlobeNewswire October 9, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire August 14, 2024

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

GlobeNewswire August 7, 2024

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

GlobeNewswire June 17, 2024

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

GlobeNewswire June 5, 2024

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

GlobeNewswire May 20, 2024

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

GlobeNewswire May 15, 2024

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

GlobeNewswire May 15, 2024

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

GlobeNewswire May 9, 2024

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

GlobeNewswire April 18, 2024

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

GlobeNewswire April 3, 2024

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

GlobeNewswire March 27, 2024

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

GlobeNewswire March 7, 2024

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

GlobeNewswire February 28, 2024

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

GlobeNewswire February 7, 2024

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

GlobeNewswire January 29, 2024

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

GlobeNewswire January 16, 2024

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

GlobeNewswire December 19, 2023